Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of BGB-43395 in Healthy Volunteers
NCT06761898Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bgb-43395 in breast cancer and solid tumor (2 arms), sponsored by BeiGene. Primary endpoints: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity, Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration and 5 more. Started Jan 2025; status: completed.
02
Drugs
bgb-43395
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06761898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761898.